1. Epidemiology and Burden of Disease

Sepsis affects millions of individuals globally each year and carries a high mortality rate. It disproportionately impacts intensive care unit (ICU) populations and underserved communities, representing a significant public health challenge and a major driver of healthcare resource utilization.

• Global Incidence: An estimated 49 million cases occur annually, with a mortality rate ranging from 17% to 33%, depending on the region and available healthcare resources.
• ICU Burden: Sepsis is the primary diagnosis for approximately 30% of all ICU admissions and is a leading cause of death in non-coronary ICUs.
• Geographic and Socioeconomic Disparities: Low- and middle-income countries report up to double the incidence of sepsis compared to high-income settings. Within developed nations, racial and ethnic minorities and individuals of low socioeconomic status often experience delayed presentation and higher mortality rates.
• Impact of Performance Programs: Adherence to evidence-based sepsis bundles—including rapid antibiotic administration, goal-directed fluid resuscitation, and lactate monitoring—has been shown to lower mortality by 2–5%.

2. Pathophysiology of Sepsis and Septic Shock

Sepsis is not merely an infection but a dysregulated host response to it. This aberrant response triggers a cascade of systemic inflammation, endothelial damage, coagulopathy, and metabolic chaos, ultimately leading to organ failure and shock.

• Immune Activation: Pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) engage Toll-like receptors on immune cells. This sparks a “cytokine storm,” characterized by the massive release of pro-inflammatory mediators like TNF-α, IL-1β, and IL-6, which increases vascular permeability and causes distributive shock.
• Immunoparalysis: Following the initial hyper-inflammatory phase, a compensatory anti-inflammatory response syndrome (CARS) can occur. This phase, marked by elevated IL-10 and widespread lymphocyte apoptosis, renders the patient susceptible to secondary infections.
• Endothelial and Microcirculatory Dysfunction: The protective glycocalyx lining the endothelium is shed, leading to capillary leak. Impaired microcirculatory autoregulation further reduces tissue oxygen delivery, independent of systemic blood pressure.
• Coagulopathy: Widespread expression of tissue factor triggers massive thrombin generation, leading to the formation of microthrombi in small vessels. This consumptive coagulopathy contributes to organ ischemia and is reflected in laboratory tests as an elevated D-dimer and prolonged prothrombin time (PT).
• Metabolic Derangements: Severe mitochondrial dysfunction impairs aerobic respiration, forcing a shift to anaerobic glycolysis even in the presence of adequate oxygen. The resulting lactate production (>2 mmol/L) is a key marker of tissue distress and poor prognosis.

3. Risk Factors Modifying Sepsis Presentation

A patient’s underlying health status and social context significantly influence their risk of developing sepsis and their clinical course. Both chronic comorbidities and social determinants of health can alter immune defenses, delay care, and worsen outcomes.

A. Chronic Comorbidities

Pre-existing diseases can impair the body’s ability to fight infection and tolerate the physiologic stress of sepsis, often requiring tailored monitoring and therapeutic adjustments.

• Diabetes Mellitus: Impairs neutrophil function, chemotaxis, and phagocytosis. Glycemic variability worsens oxidative stress and endothelial dysfunction. The recommended target blood glucose in the ICU is 140–180 mg/dL.
• Chronic Kidney Disease (CKD): The uremic state suppresses leukocyte activity and cytokine production. Doses of renally cleared antimicrobials must be adjusted to prevent accumulation and toxicity.
• Immunocompromised States: Patients with neutropenia, advanced HIV, or solid organ transplants may exhibit a blunted febrile response and other atypical signs of infection. A lower threshold for suspicion and broader initial antimicrobial coverage are necessary.

B. Social Determinants of Health

Non-biological factors, including access to care, health literacy, and systemic inequities, are powerful drivers of delayed diagnosis, treatment, and worse sepsis outcomes.

• Medication Access and Adherence: “Pharmacy deserts,” high medication costs, and lack of insurance can prevent or delay patients from starting crucial therapies for an initial infection.
• Health Literacy: Limited understanding of infection signs and symptoms can lead to delays in seeking care. Targeted patient education and telehealth follow-up can help bridge this gap.
• Socioeconomic Barriers: Lack of reliable transportation, housing instability, and food insecurity are associated with higher rates of hospital readmission for sepsis.
• Structural Inequities: Implicit bias in clinical encounters and reduced access to high-quality hospitals can contribute to disparities in care and outcomes among minority populations.

4. Clinical Manifestations and Spectrum

Sepsis exists on a spectrum, from uncomplicated infection to organ dysfunction and, ultimately, refractory septic shock. The Sepsis-3 definitions, along with clinical scoring systems and triggers, facilitate prompt recognition and intervention.

A. Sepsis-3 Definitions

• Sepsis: Defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Clinically, this is identified by an acute change in the total Sequential Organ Failure Assessment (SOFA) score of ≥2 points.
• Septic Shock: A subset of sepsis in which underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality. It is identified by the need for a vasopressor to maintain a mean arterial pressure (MAP) ≥65 mm Hg AND a serum lactate level >2 mmol/L after adequate fluid resuscitation.

B. Hemodynamic Instability and Organ Dysfunction

The clinical picture of sepsis is one of progressive physiologic failure. Key signs include:

• Hemodynamics: MAP <65 mm Hg, tachycardia >90 bpm, cool or mottled extremities, and a prolonged capillary refill time (>3 seconds). The first-line vasopressor to correct hypotension is norepinephrine.
• Early Recognition Triggers: The quick SOFA (qSOFA) score (Respiratory Rate ≥22/min, Altered Mentation, Systolic Blood Pressure ≤100 mm Hg) can identify patients outside the ICU at risk for poor outcomes. Serum lactate is a more sensitive marker of tissue hypoperfusion and should be repeated at 2 hours to assess clearance.